H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on Collegium Pharmaceutical (COLL) to $46 from $44 and keeps a Buy rating on the shares. The company reported a Q3 beat and its cash generation remains underappreciated, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceutical Reports Record Q3 2025 Results
- Collegium Pharmaceutical Reports Strong Q3 2025 Financial Results
- Collegium raises FY25 revenue view to $775M-$785M from $745M-$760M
- Collegium Pharmaceutical reports Q3 adjusted EPS $2.25, consensus $1.86
- Collegium Pharmaceutical Inc. (COLL) Q3 Earnings Cheat Sheet